Jefferies Reiterates Buy Rating on aTyr Pharma (ATYR): "view an immediate approval of EFZO‑FIT as low probability"
Tweet Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating and $3.00 price target on aTyr Pharma (NASDAQ: ATYR)The analyst commented, "Our ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
